Navigation Links
New Gastric Cancer Drug Unlikely to Benefit Kidney Cancer Patients

An article appearing in the January issue of The Journal of Urology says that drugs used to treat gastrointestinal stromal cancers (GISTs) are likely to be ineffective for// patients with full blown kidney cancer.

These findings are reported by investigators at the Mayo Clinic Cancer Center, who say that the drug in question is not going to help patients with high grade renal cell carcinoma. "While this finding does not seem like good news for patients with kidney cancer," said Bradley Leibovich, M.D., Mayo Clinic urologist and lead investigator of the study, "it does help us to narrow down the treatment options among the new targeted therapy drugs and would seem to indicate that resources for investigating potential new kidney cancer therapies may be better utilized on other options."

The current study wanted to verify a previous study published in 2004 in The Journal of Clinical Pathology. They reviewed the data of all patients who had undergone partial or radical nephrectomy between 1970 and 2002. This study had found that kidney tumors often expressed KIT (a receptor kinase tyrosine) mutations. Another study appearing in The Journal of Urology had also reported on the prevalence of these type of mutations in kidney tumors. Dr. Leibovich's team wanted to verify these findings since these tumors are very aggressive and recur even after surgery. If the findings were corroborated, then new drugs could have been used in the treatment process. But the researchers found no evidence of this since only 4.5 percent of tumors exhibited KIT mutations. "Imatinib only would have had the potential to be helpful to that small percentage of patients that we found to have a KIT-positive tumor," says lead author Shomik Sengupta, M.D. "And even then it would only work if they also had specific mutations that would respond to the drug." These findings led the researchers to conclude that imatinib therapy could not be justified in all kidney cancer. "Tumors that express KIT but lack KIT mutations may not respond to imatinib and other researchers have shown that recently for adenoid and small cell lung cancers. Because we rarely found KIT expression and no KIT mutations, we cannot justify imatinib therapy," Dr Leibovich concluded.

John Cheville, M.D.; Christine Lohse; Eugene Kwon, M.D.; Horst Zincke, M.D., Ph.D.; and Michael Blute, M.D. They were joined by Christopher Corless, M.D., Ph.D., from the Oregon Cancer Institute, and Michael Heinrich, M.D., from Oregon Health and Science University, both in Portland also contributed to this study. For more information visit mayoclinic.org/kidneycancer-rst.

Contact
Mayo Clinic
200 First St. SW
Rochester, MN 55902
United States
http://www.mayo.edu/news

'"/>




Related medicine news :

1. The Reason For Loss Of Appetite After Gastric Bypass
2. Gastric bypass surgery reduces risk of heart disease
3. Surgeons Perform Robotic Gastric Bypass Surgery
4. Helicobacter pylori Antibiotic Treatment of Peptic Ulcer May not Prevent Gastric lymphomas
5. Migraine Patients Suffer From Gastric Stasis
6. Gastric Bypass And Laparoscopic Reflux Surgery Gaining Popularity
7. Gastric bypass can cause deficiency of Vitamin A
8. For Super-Obese Patients, Duodenal Switch Beats Gastric Bypass
9. Long-time Gastric Acid Suppression Does Not Increase The Risk Of Cancer
10. Gastric Bypass Surgery May Lead to Increased Kidney Stone Risk
11. Robotically Assisted Colo-resection And Gastric Bypass Surgeries Are Becoming Popular
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2016)... ... May 26, 2016 , ... On Memorial Day, Hope ... lost their lives in military battle for the country. The nonprofit Hope For ... provide more programs that empower independence for disabled military veterans, as well as police, ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... The ... Project offering a new model of care for living and healing, celebrated its ... values: Meaningful Life in a Real Home provided by Empowered Staff. , “This is ...
(Date:5/26/2016)... Pittsburgh, PA (PRWEB) , ... May 26, 2016 ... ... transplantation, and one that has a significant negative impact on long-term patient survival, ... to date. The results, published online this week in the Journal of Thoracic ...
(Date:5/26/2016)... ... , ... There are nearly 14.5 million people living with and beyond cancer ... June 5, 2016, communities around the world will gather to recognize these cancer survivors ... Survivors Day® is an annual worldwide Celebration of Life that is held on the ...
(Date:5/26/2016)... ... May 26, 2016 , ... MadgeTech will be showcasing its line of ... New Hampshire at the MadgeTech headquarters. With products sold in more than 100 countries ... agencies, including NASA. , In 2012, NASA strategically set up 17 RHTemp101A ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... New York , May 26, 2016 ... Market Research "Medical Waste Management Market - U.S. Industry Analysis, ... medical waste management market in the U.S. was valued at ... at a CAGR of 3.4% from 2015 to 2023 to ... provides exhaustive analysis of current and emerging needle free drug ...
(Date:5/26/2016)... 26, 2016 A key trend ... the emergence of new treatments. Cardax, a development stage ... treatment. The therapy is expected to fulfil large unmet ... is conducting studies to develop new treatments for osteoarthritis. ... genes involved in osteoarthritis are being investigated, and early ...
(Date:5/26/2016)... , May 26, 2016 ... Associated With Both Cost Savings and Overall ... plc (LSE: BTG), an international specialist healthcare company, ... at the 21st Annual Meeting of ISPOR (International ... treatment of hepatocellular carcinoma (HCC) using yttrium-90 glass ...
Breaking Medicine Technology: